Join our daily newsletter At The Bell to receive exclusive market insights
- Immutep (IMM) is granted a Japanese patent for its pre-clinical product candidate, IMP761, valid until 2036
- The patent is entitled “Anti-LAG-3 Antibodies” and was granted by the Japanese Patent Office
- The new patent follows the grant of the equivalent European patent announced last year for IMP761 and its use to treat T-cell mediated inflammatory and autoimmune diseases
- CEO Marc Voigt says the company is continuing to take important steps to protect the pre-clinical product candidate
- Immutep shares are up 3.17 per cent and trading at 32.5 cents each at 10:22 am AEST
Immutep (IMM) has been granted a Japanese patent for its pre-clinical product candidate, IMP761.
The patent for Immutep’s IMP761 is entitled “Anti-LAG-3 Antibodies” and was granted by the Japanese Patent Office.
The new patent follows the grant of the equivalent European patent announced in October 2022 for Immutep’s pre-clinical product candidate IMP761, along with pharmaceutical compositions comprising the candidate and the use of it to treat T-cell mediated inflammatory and autoimmune diseases.
CEO Marc Voigt said the company is continuing to take important steps to protect IMP761.
“… the LAG-3 immune control mechanism has attracted a great deal of attention in recent months because of the approval by the FDA of the first LAG-3 related product in immuno-oncology,” Marc Voigt said.
“With deep expertise in LAG-3 biology, four LAG3 product candidates in development, and a comprehensive patent estate, Immutep is well placed to make important contributions to this rapidly emerging field of immunotherapy – in both cancer and autoimmune diseases.”
Immutep has been working towards advancing IMP761 for clinical testing and has been collaborating with Northway Biotech to develop a GMP compliant manufacturing process using the cell line developed by Batavia BioSciences.
The Japanese patent is valid until September 2036.
Immutep shares were up 3.17 per cent and trading at 32.5 cents each at 10:22 am AEST.
